Xylem Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Xylem Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.04B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.56B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.36B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $5.52B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $5.20B | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $1.37B | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $1.22B | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $1.16B | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $1.12B | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $1.37B | Feb 26, 2021 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.04B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $8.56B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.36B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $5.52B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $5.20B | Feb 28, 2024 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.28B | Feb 23, 2018 |
| FY2017 | Sep 30, 2017 | $1.20B | Feb 23, 2018 |
| FY2017 | Jun 30, 2017 | $1.16B | Feb 23, 2018 |
| FY2017 | Mar 31, 2017 | $1.07B | Feb 23, 2018 |
| FY2017 | Dec 31, 2016 | $1.10B | Feb 23, 2018 |
| FY2017 | Sep 30, 2016 | $897.00M | Feb 23, 2018 |
| FY2017 | Jun 30, 2016 | $932.00M | Feb 23, 2018 |
| FY2017 | Mar 31, 2016 | $847.00M | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $994.00M | Feb 23, 2017 |
| FY2016 | Sep 30, 2015 | $902.00M | Feb 23, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.21B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $2.72B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $2.08B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $1.98B | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $526.00M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $461.00M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $434.00M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $409.00M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $537.00M | Feb 26, 2021 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $957.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $890.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $609.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $355.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $427.00M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $148.00M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $37.00M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $31.00M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $38.00M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $118.00M | Feb 26, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.22B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.01B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $652.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $622.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $585.00M | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | $179.00M | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | $73.00M | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | $54.00M | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | $61.00M | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | $195.00M | Feb 26, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $230.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $232.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $206.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $204.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $187.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $191.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $189.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $181.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $110.00M | Feb 22, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.92B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.91B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $1.76B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $1.23B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $1.18B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $1.14B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $1.16B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $1.16B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $1.09B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $914.00M | Feb 22, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.24B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.26B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $837.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $596.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $538.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $824.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $839.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $586.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $686.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $497.00M | Feb 22, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $17.63B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $16.49B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $16.11B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $7.95B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $8.28B | Feb 24, 2023 |
| FY2022 | Dec 31, 2020 | $8.75B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $7.71B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $7.22B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $6.86B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $6.47B | Feb 22, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.89B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $5.61B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $5.94B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $4.45B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $5.05B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $5.77B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $4.74B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $4.44B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $4.34B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $4.27B | Feb 23, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $10.64B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $10.17B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $3.49B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $3.22B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $2.97B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $2.96B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $2.77B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $2.50B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $2.19B | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.33B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $7.98B | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $7.59B | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $2.72B | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $2.79B | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $2.85B | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $2.84B | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $2.98B | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $2.77B | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $2.63B | Feb 22, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.71B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $3.14B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $2.60B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $2.29B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $2.15B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.93B | Feb 25, 2022 |
| FY2020 | Dec 31, 2019 | $1.87B | Feb 26, 2021 |
| FY2019 | Dec 31, 2018 | $1.64B | Feb 28, 2020 |
| FY2018 | Dec 31, 2017 | $1.23B | Feb 22, 2019 |
| FY2017 | Dec 31, 2016 | $1.03B | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.48B | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $1.12B | Feb 25, 2026 |
| FY2024 | Dec 31, 2023 | $1.02B | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $944.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.35B | Feb 24, 2023 |
| FY2021 | Dec 31, 2020 | $1.88B | Feb 25, 2022 |
| FY2021 | Dec 31, 2019 | $724.00M | Feb 25, 2022 |
| FY2021 | Dec 31, 2018 | $296.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | $414.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | $308.00M | Feb 28, 2020 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.95B | Feb 25, 2026 |
| FY2024 | Dec 31, 2024 | $2.03B | Mar 3, 2025 |
| FY2012 | Dec 31, 2012 | $1.21B | Feb 25, 2013 |
| FY2012 | Dec 31, 2011 | $1.21B | Feb 25, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 3 | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | 1 | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 28, 2024 |
| FY2020 | Dec 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Sep 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Jun 30, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Mar 31, 2020 | 0 | Feb 26, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Feb 26, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 243.58M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | 242.99M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | 241.50M | Feb 25, 2026 |
| FY2025 | Dec 31, 2022 | 180.25M | Feb 25, 2026 |
| FY2024 | Dec 31, 2021 | 180.39M | Mar 3, 2025 |
| FY2023 | Dec 31, 2020 | 180.35M | Feb 28, 2024 |
| FY2022 | Dec 31, 2019 | 180.14M | Feb 24, 2023 |
| FY2021 | Dec 31, 2018 | 179.72M | Feb 25, 2022 |
| FY2020 | Dec 31, 2017 | 179.86M | Feb 26, 2021 |
| FY2019 | Dec 31, 2016 | 179.37M | Feb 28, 2020 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $391.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2024 | $350.00M | Feb 25, 2026 |
| FY2025 | Dec 31, 2023 | $299.00M | Feb 25, 2026 |
| FY2024 | Dec 31, 2022 | $217.00M | Mar 3, 2025 |
| FY2023 | Dec 31, 2021 | $203.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $188.00M | Feb 24, 2023 |
| FY2021 | Dec 31, 2019 | $174.00M | Feb 25, 2022 |
| FY2020 | Dec 31, 2018 | $152.00M | Feb 26, 2021 |
| FY2019 | Dec 31, 2017 | $130.00M | Feb 28, 2020 |
| FY2018 | Dec 31, 2016 | $112.00M | Feb 22, 2019 |